US-based medical technology company Iantrek has secured $42m in a Series C funding round, led by US Venture Partners.
The round also saw participation from aMoon Fund and several current investors.
Iantrek intends to use the financing to support the US launch of its novel glaucoma treatment, AlloFlo Uveo, and bolster its wider pipeline development efforts.
USVP general partner Casey Tansey said: “This raise reflects strong confidence in Iantrek’s bold vision and disruptive approach to interventional glaucoma.”
aMoon Fund general partner Todd Sone said: “We are looking forward to working with Adam Szaronos, Dr. Sean Ianchulev, and the whole team on their mission to provide next-generation glaucoma treatment to the many thousands of patients in need.”
Glaucoma is a significant health concern, causing irreversible optic nerve damage, and is traditionally managed through intraocular pressure reduction.
Unlike existing minimally invasive glaucoma surgery (MIGS) devices that target the trabecular pathway, AlloFlo Uveo uniquely accesses the less explored uveoscleral route.
A peer-reviewed study in Ophthalmology Science released this year by the American Academy of Ophthalmology highlighted the effectiveness of AlloFlo Uveo.
The study showed a 34% reduction in intraocular pressure after two years and a significant decrease in the need for IOP-lowering medications.
Besides, the study showed “no serious” adverse events linked to the device, confirming its safety profile.
Iantrek CEO Adam Szaronos said: “Our mission is to address a major unmet need in glaucoma care, and this fundraise marks a pivotal moment in helping us achieve it.
“More than 2.5 million eyes in the U.S. are experiencing waning efficacy from previous Minimally Invasive Glaucoma Surgery (MIGS) procedures targeting the trabecular pathway.
“AlloFlo Uveo enables access to the uveoscleral pathway, the eye’s other natural drainage system, much like giving a thoracic surgeon the ability to enhance the second lung.”
Founded by ophthalmologist Sean Ianchulev, Iantrek focuses on developing bio-interventional and micro-interventional ophthalmic products.
The company’s product range includes AlloFlo Uveo, AlloSert Uveo, and C.Rex, designed to enhance surgical precision and access to ocular outflow pathways.
AlloFlo Uveo is the first allogeneic graft designed for long-term implantation and bio-integration in eye surgeries.
The company has concluded initial human testing for its next bio-interventional product, which is anticipated to launch commercially in 2026.
Iantrek board chairman Sean Ianchulev said: “With approximately 3,000 procedures performed through its early access programme, surgeon demand for uveoscleral pathway access is clear.
“Iantrek’s bio-interventional approach is currently the only surgical solution targeting this major outflow pathway with the highest therapeutic index in glaucoma treatment.”
